Long term inhibition of complement C1s in patients with cold agglutinin disease: results from a named patient program

被引：0

作者：

Jilma, B. ^{[1
]}

Gelbenegger, G. ^{[1
]}

Derhaschnig, U. ^{[1
]}

Sillaber, C. ^{[2
]}

D'Sa, S. ^{[3
]}

Fillitz, M. ^{[4
]}

Schenk, T. ^{[5
]}

Gilbert, J. ^{[6
]}

Cartwright, R. ^{[7
]}

Jaeger, U. ^{[2
]}

机构：

[1] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria

[2] Med Univ Vienna, Dept Internal Med 1, Div Hematol, Vienna, Austria

[3] Univ Coll London Hosp NHS Fdn Trust, UCLH Ctr Waldenstroms Macroglobulinaemia & Relate, London, England

[4] Hanusch Hosp, Dept Internal Med, Vienna, Austria

[5] Univ Klinikum St Polten, Dept Internal Med, St Polten, Austria

[6] Band Therapeut, Lexington, MA USA

[7] Worthing Hosp Western Sussex Hosp, Worthing, England

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V46

引用

页码：9 / 9

页数：1

共 50 条

[31] The molecular basis for C1s inhibition by Lyme disease spirochetes
Thomas, Sheila
Garrigues, Ryan
Leong, John
Garcia, Brandon
[J]. IMMUNOBIOLOGY, 2023, 228 (05) : 28 - 28
[32] Serologic Response to Meningococcal Vaccination in Patients with Cold Agglutinin Disease (CAD) in the New Era of Complement Inhibition
Alashkar, Ferras
Herich-Terhuerne, Doerte
Preising, Nicole
Duehrsen, Ulrich
Ulrich, Vogel
Roeth, Alexander
[J]. BLOOD, 2018, 132
[33] Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibition
Alashkar, Ferras
Vance, Colin
Herich-Terhuerne, Dorte
Turki, Amin T.
Schmitz, Christine
Bommer, Martin
Huettmann, Andreas
Duehrsen, Ulrich
Vogel, Ulrich
Roeth, Alexander
[J]. VACCINE, 2019, 37 (44) : 6682 - 6687
[34] INHIBITION OF PLATELET COLLAGEN INTERACTIONS BY THE C1S SUBCOMPONENT OF THE 1ST COMPONENT OF COMPLEMENT
WAUTIER, JL
LEGRAND, YJ
FAUVEL, F
CAEN, JP
[J]. THROMBOSIS RESEARCH, 1981, 21 (1-2) : 3 - 12
[35] C1s-targeted inhibition of classical complement pathway by sutimlimab in cold agglutinin disease (CAD): Efficacy and safety results from the randomized, placebo (PBO)-controlled phase 3 CADENZA study
Roth, A.
Berentsen, S.
Barcellini, W.
D'Sa, S.
Jilma, B.
Michel, M.
Weitz, I. C.
Yamaguchi, M.
Nishimura, J., I
Vos, J. M., I
Patel, P.
Schaible, B.
Jiang, X.
Vagge, D. S.
Wardecki, M.
Shafer, F.
Lee, M.
Broome, C. M.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 40 - 41
[36] Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients
Jaeger, Ulrich
D'Sa, Shirley
Schoergenhofer, Christian
Bartko, Johann
Sillaber, Christian
Jilma-Stohlawetz, Petra
Fillitz, Michael
Schenk, Thomas
Patou, Gary
Panicker, Sandip
Parry, Graham C.
Gilbert, James C.
Jilma, Bernd
[J]. BLOOD, 2017, 130
[37] Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor
Peerschke, Ellinor I. B.
Panicker, Sandip
Bussel, James
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (06) : 942 - 945
[38] Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension
Roeth, Alexander
Broome, Catherine M.
Barcellini, Wilma
Jilma, Bernd
Hill, Quentin A.
Cella, David
Tvedt, Tor Henrik Anderson
Yamaguchi, Masaki
Murakhovskaya, Irina
Lee, Michelle
Shafer, Frank
Wardecki, Marek
Jayawardene, Deepthi
Yoo, Ronnie
Msihid, Jerome
Weitz, Ilene C.
[J]. ECLINICALMEDICINE, 2024, 74
[39] PURIFICATION OF C1S, A SUBUNIT OF FIRST COMPONENT OF COMPLEMENT FROM HUMAN PLASMA
OKAMURA, K
MURAMATU, M
FUJII, S
[J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1973, 295 (01) : 252 - 257
[40] Complement C1s deficiency in a male Caucasian patient with systemic lupus erythematosus: a case report
Kleer, Jessica S.
Skattum, Lillemor
Dubler, Denise
Fischer, Ingeborg
Zgraggen, Armin
Mundwiler, Esther
Kim, Min Jeong
Trendelenburg, Marten
[J]. FRONTIERS IN IMMUNOLOGY, 2024, 14

← 1 2 3 4 5 →